{"type":"trials","record":{"id":42265,"source_id":"clinicaltrials-gov","external_id":"NCT02125864","title":"Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept","brief_summary":"The purpose of this study is to examine the plasma concentration of vascular endothelial growth factor (VEGF) after standard treatment with one of the newest growth factor inhibitors, aflibercept (Eylea). Patients with exudative age-related macular degeneration (AMD) are treated today with anti-growth factors (anti-VEGF). Eylea appears to have a longer duration of action in the eye and a more powerful effect on the edema in the macula than previously used growth factor inhibitors. This means that the disease can be controlled with fewer number of injections into the eye and the investigators can therefore reduce the risk of complications associated with this type of treatment. It is unclear what the plasma VEGF concentration after treatment with Eylea into the eye in patients with wet age-related macular degeneration is.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Oslo University Hospital","enrollment":16,"countries":[],"start_date":"2014-04-01","completion_date":"2014-11-01","last_update_date":"2022-04-27","source_url":"https://clinicaltrials.gov/study/NCT02125864","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"Eylea-2014","age_range":"60 Years","comparator":null,"organization":"Oslo University Hospital","interventions":["intravitreal injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change in VEGF plasma concentration (pg/mL) — 6 months","Mean change in Visual Acuity as measured with the Snellen chart — 6 months","Central Retinal Thickness as measured by Optical coherence tomography expressed in microns — 6 months","Number of non-responders — 6 months"],"design_description":"NA · SINGLE GROUP · BASIC SCIENCE · NONE","source_has_results":false},"controlled_terms":["Exudative Age-related Macular Degeneration","intravitreal injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02125864","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-04-01 to 2014-11-01","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.943Z","intervention":["intravitreal injection"],"participants":16,"study_design":"NA · SINGLE GROUP · BASIC SCIENCE · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change in VEGF plasma concentration (pg/mL) — 6 months","Mean change in Visual Acuity as measured with the Snellen chart — 6 months","Central Retinal Thickness as measured by Optical coherence tomography expressed in microns — 6 months","Number of non-responders — 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42265","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}